Progressive improvement in atopic dermatitis symptoms was found with continued tralokinumab plus topical corticosteroids, according to a study.
“This study is a post-hoc analysis of the ECZTRA 3 clinical trials assessing the impact of tralokinumab over a 32-week treatment period. It included all patients who initiated tralokinumab, irrespective of the response at week 16,” Adriana Guana, MD, vice president of U.S. medical affairs for LEO Pharma, told Healio. “This study is most reflective of clinical practice because biologics are commonly used in combination with topical